Jonsson Comprehensive Cancer Center
🇺🇸United States
Clinical Trials
379
Active:42
Completed:164
Trial Phases
6 Phases
Early Phase 1:17
Phase 1:109
Phase 2:114
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (342 trials with phase data)• Click on a phase to view related trials
Phase 2
114 (33.3%)Phase 1
109 (31.9%)Not Applicable
84 (24.6%)Early Phase 1
17 (5.0%)Phase 3
17 (5.0%)Phase 4
1 (0.3%)Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
Not Applicable
Not yet recruiting
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast CarcinomaAnatomic Stage I Breast Cancer AJCC v8Invasive Breast CarcinomaLocalized Estrogen Receptor-Positive Breast Carcinoma
- Interventions
- Procedure: Biospecimen CollectionOther: Questionnaire AdministrationProcedure: Radiologic Imaging Procedure
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT07191717
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
Not Applicable
Not yet recruiting
- Conditions
- Prostate Carcinoma
- Interventions
- Procedure: Computed TomographyDrug: Fluorine F 18 FlotufolastatProcedure: Positron Emission TomographyProcedure: Ultrasound-Guided Prostate Biopsy
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 81
- Registration Number
- NCT07185165
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
Not Applicable
Not yet recruiting
- Conditions
- Prostate Carcinoma
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT07164027
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
Not Applicable
Not yet recruiting
- Conditions
- Oligometastatic Prostate AdenocarcinomaRecurrent Prostate Adenocarcinoma
- Interventions
- Drug: Actinium Ac 225 Vipivotide TetraxetanProcedure: Biospecimen CollectionOther: Gallium Ga 68 GozetotideProcedure: PSMA PET-CT ScanRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 107
- Registration Number
- NCT07150715
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Not Applicable
Recruiting
- Conditions
- Anal CarcinomaBladder CarcinomaBreast CarcinomaCervical CarcinomaCholangiocarcinomaColorectal CarcinomaEsophageal CarcinomaGastric CarcinomaHead and Neck CarcinomaHematopoietic and Lymphatic System Neoplasm
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT07118176
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 76
- Next
News
No news found